What is the current Price Target for the Avenue Therapeutics, Inc. stock?

The average Avenue Therapeutics, Inc. target price is $8.00. This is 2,852.03% higher than the current stock price. 1 Analyst has issued a Avenue Therapeutics, Inc. price target 2026.

How high will the Avenue Therapeutics, Inc. stock rise?

No reliable answer can be given as to how high the Avenue Therapeutics, Inc. stock will rise. The performance of stocks, including the Avenue Therapeutics, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Avenue Therapeutics, Inc. stock today?

The performance of Avenue Therapeutics, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Avenue Therapeutics, Inc. stock fall?

The decline in Avenue Therapeutics, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Avenue Therapeutics, Inc. Forecast, price target & analysts

$0.25

7.68% today

Nasdaq, Apr 04, 08:10 pm CET

ISIN

US05360L2051

Symbol

ATXI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Avenue Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Avenue Therapeutics, Inc. Classifications & Recommendation:

Buy

100%

Avenue Therapeutics, Inc. Price Target

Target Price	$8.00
Price	$0.27
Potential	2,852.03% register free of charge
Number of Estimates	1

	1 Analyst has issued a Avenue Therapeutics, Inc. price target 2026. The average Avenue Therapeutics, Inc. target price is $8.00. This is 2,852.03% register free of charge higher than the current stock price.
	A rating was issued by 1 analysts: 1 Analysts recommend Avenue Therapeutics, Inc. to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Avenue Therapeutics, Inc. stock has an average upside potential 2026 of 2,852.03% register free of charge . Most analysts recommend the Avenue Therapeutics, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-9.00	-1.96
	87.75%	78.22%
P/E		negative

1 Analysts have issued a Avenue Therapeutics, Inc. forecast for earnings per share. The average Avenue Therapeutics, Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-9.00	87.75%
2025	$-1.96 78.22% Unlock
2026	$-1.84 6.12% Unlock
2027	$-2.24 21.74% Unlock
2028	$1.09 148.66% Unlock

Current	-0.02	75.00%
2025	-0.18 800.00% Unlock
2026	-0.19 5.56% Unlock
2027	-0.16 15.79% Unlock
2028	0.33 306.25% Unlock

Avenue Therapeutics, Inc....

Discover more stocks with a high price target

Novo Nordisk 83.92%

Coinbase Global, Inc. 83.53%

BioNTech SE - ADR 50.09%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now